310 related articles for article (PubMed ID: 37217281)
1. Advances in Immunocompetent Mouse and Rat Models.
Bu W; Li Y
Cold Spring Harb Perspect Med; 2024 Mar; 14(3):. PubMed ID: 37217281
[TBL] [Abstract][Full Text] [Related]
2. Intraductal Injection of Lentivirus Vectors for Stably Introducing Genes into Rat Mammary Epithelial Cells in Vivo.
Bu W; Li Y
J Mammary Gland Biol Neoplasia; 2020 Dec; 25(4):389-396. PubMed ID: 33165800
[TBL] [Abstract][Full Text] [Related]
3. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.
Annunziato S; Kas SM; Nethe M; Yücel H; Del Bravo J; Pritchard C; Bin Ali R; van Gerwen B; Siteur B; Drenth AP; Schut E; van de Ven M; Boelens MC; Klarenbeek S; Huijbers IJ; van Miltenburg MH; Jonkers J
Genes Dev; 2016 Jun; 30(12):1470-80. PubMed ID: 27340177
[TBL] [Abstract][Full Text] [Related]
4. In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
Annunziato S; Lutz C; Henneman L; Bhin J; Wong K; Siteur B; van Gerwen B; de Korte-Grimmerink R; Zafra MP; Schatoff EM; Drenth AP; van der Burg E; Eijkman T; Mukherjee S; Boroviak K; Wessels LF; van de Ven M; Huijbers IJ; Adams DJ; Dow LE; Jonkers J
EMBO J; 2020 Mar; 39(5):e102169. PubMed ID: 31930530
[TBL] [Abstract][Full Text] [Related]
5. Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice.
Bu W; Creighton CJ; Heavener KS; Gutierrez C; Dou Y; Ku AT; Zhang Y; Jiang W; Urrutia J; Jiang W; Yue F; Jia L; Ibrahim AA; Zhang B; Huang S; Li Y
Sci Adv; 2023 May; 9(19):eade0059. PubMed ID: 37172086
[TBL] [Abstract][Full Text] [Related]
6. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.
Verbeke S; Richard E; Monceau E; Schmidt X; Rousseau B; Velasco V; Bernard D; Bonnefoi H; MacGrogan G; Iggo RD
Breast Cancer Res; 2014 Dec; 16(6):504. PubMed ID: 25527189
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 therapies in experimental mouse models of cancer.
Estêvão D; Rios Costa N; da Costa RG; Medeiros R
Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
[TBL] [Abstract][Full Text] [Related]
8. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.
Irshad S; Abate-Shen C
Cancer Metastasis Rev; 2013 Jun; 32(1-2):109-22. PubMed ID: 23114843
[TBL] [Abstract][Full Text] [Related]
9. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
10. The RCAS-TVA system for introduction of oncogenes into selected somatic mammary epithelial cells in vivo.
Reddy JP; Li Y
J Mammary Gland Biol Neoplasia; 2009 Dec; 14(4):405-9. PubMed ID: 19936988
[TBL] [Abstract][Full Text] [Related]
11. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.
Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B
Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464
[TBL] [Abstract][Full Text] [Related]
12. The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors: a new model for the chemoprevention of premalignant and malignant lesions of the breast.
Gould MN
J Cell Biochem Suppl; 1993; 17G():66-72. PubMed ID: 8007712
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Gene Delivery into Mouse Mammary Epithelial Cells Through Mammary Intraductal Injection.
Bu W; Li Y
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36847377
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.
Menezes ME; Das SK; Emdad L; Windle JJ; Wang XY; Sarkar D; Fisher PB
Adv Cancer Res; 2014; 121():331-382. PubMed ID: 24889535
[TBL] [Abstract][Full Text] [Related]
15. Advances in mouse models of prostate cancer.
Ahmad I; Sansom OJ; Leung HY
Expert Rev Mol Med; 2008 Jun; 10():e16. PubMed ID: 18538039
[TBL] [Abstract][Full Text] [Related]
16. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mouse models for the prevention of breast cancer.
Shen Q; Brown PH
Mutat Res; 2005 Aug; 576(1-2):93-110. PubMed ID: 15888345
[TBL] [Abstract][Full Text] [Related]
18. Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer.
Borowsky AD
Cold Spring Harb Perspect Biol; 2011 Sep; 3(9):a009670. PubMed ID: 21646376
[TBL] [Abstract][Full Text] [Related]
19. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Hoenerhoff MJ; Shibata MA; Bode A; Green JE
Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
[TBL] [Abstract][Full Text] [Related]
20. The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.
van der Weyden L; Jonkers J; Adams DJ
Curr Opin Genet Dev; 2021 Feb; 66():57-62. PubMed ID: 33429291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
